Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709438 | 1.00 | FGFR1 (0.35) | FGFR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6280958 | 0.82 | FGFR1 (0.33) | FGFR1NPC1RAB9A | |
| SCHEMBL6280959 | 0.82 | FGFR1 (0.33) | FGFR1NPC1RAB9A | |
| SCHEMBL5248821 | 0.81 | CHEK1 (0.33) | FGFR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5248808 | 0.81 | CHEK1 (0.33) | FGFR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7225599 | 0.78 | KDR (0.38) | FGFR1KMT2AKDM4EMAPT | |
| SCHEMBL28684878 | 0.77 | DGAT1 (0.38) | FGFR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29389978 | 0.77 | DGAT1 (0.38) | FGFR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28684880 | 0.77 | DGAT1 (0.38) | FGFR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6283634 | 0.74 | RET (0.35) | NPC1RAB9AKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | FGFR1 262/4885NPC1 3531/4885RAB9A 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.